ArticleCureus2025
A Case of Hypokalemia Caused by the Consumption of Licorice-Containing Herbal Tea.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypokalemia can have many etiologies, of which licorice toxicity is notable but often overlooked. Licorice is being increasingly used as a component in herbal formulations and holistic remedies. We present a case of licorice-induced hypokalemia due to herbal tea formulation in a patient with a history of type 2 diabetes mellitus and metastatic adenocarcinoma. This case highlights a unique presentation of pseudo-hyperaldosteronism due to licorice consumption with concurrent use of a sodium-glucose cotransporter (SGLT2) inhibitor, requiring a high index of suspicion for diagnosis. Glycyrrhetinic acid (GA) is one of the active metabolites of licorice, which is responsible for intracellular cortisol accumulation and activation of mineralocorticoid receptors. Therefore, in addition to removing the offending agent, mineralocorticoid receptor antagonists can also be used in treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.